Literature DB >> 8913971

Synchronous endometrioid tumors of the ovary and endometrium. A clinicopathologic study of 22 cases.

S S Falkenberry1, M M Steinhoff, M Gordinier, S Rappoport, W Gajewski, C O Granai.   

Abstract

OBJECTIVE: To analyze a group of 22 patients with synchronous endometrioid tumors of the ovary and endometrium. STUDY
DESIGN: A retrospective chart review was undertaken and information collected on patient age, parity, tumor grade and stage, presence of coexisting endometriosis and survival. Flow cytometry was determined from archival samples of the endometrial and ovarian tumors.
RESULTS: The mean age at diagnosis was 52.8 years (range 36-71); mean parity was 1.05. With regard to the endometrial component, 68.2% were grade 1, 63.6% were stage I and, by flow cytometry, 62.5% were aneuploid. With regard to the ovarian lesions, 68.2% were grade 1, 68.2% were stage I, and 71.4% were aneuploid by flow cytometry. Twelve (54.5%) of 22 patients had pathologic evidence of coexisting endometriosis. Overall, three-year survival was 75%. All 11 patients with stage I disease at both sites were alive, without disease, at a mean follow-up of 34.9 months.
CONCLUSION: Patients with synchronous endometrioid tumors of the endometrium and ovary are generally younger than reported for either endometrial adenocarcinomas or ovarian epithelial adenocarcinomas. They tend to be low grade and early stage and are frequently associated with endometriosis. Our data suggest that the survival of patients with synchronous primaries correlates with the stage of the individual tumors and that a second, synchronous primary does not adversely affect prognosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913971

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  12 in total

1.  Risk factors for developing multiple malignancies in patients with endometrial cancer.

Authors:  Stefano Uccella; Stephen S Cha; L Joseph Melton; Eric J Bergstralh; Lisa A Boardman; Gary L Keeney; Karl C Podratz; Fabio Francesco Ciancio; Andrea Mariani
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

2.  Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.

Authors:  Gulisa Turashvili; Natalia R Gómez-Hidalgo; Jessica Flynn; Mithat Gonen; Mario M Leitao; Robert A Soslow; Rajmohan Murali
Journal:  Gynecol Oncol       Date:  2018-11-06       Impact factor: 5.482

Review 3.  Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2016-04-11

Review 4.  Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Semin Diagn Pathol       Date:  2014-04-02       Impact factor: 3.464

Review 5.  Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.

Authors:  Daichi Maeda; Ie-Ming Shih
Journal:  Adv Anat Pathol       Date:  2013-01       Impact factor: 3.875

Review 6.  Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects.

Authors:  Jian-Jun Wei; Josette William; Serdar Bulun
Journal:  Int J Gynecol Pathol       Date:  2011-11       Impact factor: 2.762

7.  Premenopausal early-stage endometrial carcinoma patients with low CA-125 levels and low tumor grade may undergo ovary-saving surgery.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Woo Young Kim; Suk-Joon Chang; Hee-Jae Joo; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

8.  Inducing malignant transformation of endometriosis in rats by long-term sustaining hyperestrogenemia and type II diabetes.

Authors:  Chang-Ting Wang; Dan-Bo Wang; Kui-Ran Liu; Yan Li; Chun-Xiao Sun; Cui-Shan Guo; Fang Ren
Journal:  Cancer Sci       Date:  2014-12-18       Impact factor: 6.716

9.  Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.

Authors:  C Blake Gilks
Journal:  J Oncol       Date:  2009-12-30       Impact factor: 4.375

Review 10.  ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.

Authors:  Eleftherios P Samartzis; Aurelia Noske; Konstantin J Dedes; Daniel Fink; Patrick Imesch
Journal:  Int J Mol Sci       Date:  2013-09-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.